ATG

ATG
Name	ATG
Organism	Homo sapiens
Location	2q37
Synonyms	Autophagy-related gene
Function	Autophagy regulation

ATG ATG refers to a family of autophagy-related genes central to macroautophagy and related vesicular trafficking processes. These genes encode proteins that participate in autophagosome formation, membrane remodeling, and cargo recognition, interacting with numerous signaling networks and cellular organelles. The ATG family has been studied across model organisms and linked to diverse physiological systems, pathologies, and therapeutic strategies.

Introduction

The ATG gene family was first characterized in genetic screens in Saccharomyces cerevisiae, with homologs subsequently identified in Arabidopsis thaliana, Caenorhabditis elegans, Drosophila melanogaster, Mus musculus, and humans. Core components such as orthologs of the yeast Atg1 kinase complex and the Atg8 ubiquitin-like conjugation machinery coordinate with organelles including the endoplasmic reticulum, Golgi apparatus, and mitochondria to initiate and expand isolation membranes. Studies in laboratories at institutions like the Max Planck Society, Cold Spring Harbor Laboratory, and National Institutes of Health have connected ATG proteins to pathways regulated by kinases such as mTOR, AMPK, and signaling complexes including PI3K and the ULK1 complex.

Biology and Genetics

ATG genes encode proteins organized into functional groups: initiation kinases, membrane nucleation complexes, ubiquitin-like conjugation systems, and cargo receptors. Examples include the Atg1/ULK1 kinase complex, Atg6/Beclin 1 interacting PI3K class III complexes involving VPS34 and VPS15, and the Atg8/LC3 and Atg12 conjugation machinery requiring enzymes homologous to E1 and E2 ligases. Genetic regulation involves transcription factors such as TFEB, FOXO3, and modulators like p53 that influence ATG transcription and autophagic flux. Evolutionary conservation is evident in comparative genomics from yeast to vertebrates, with paralogs and isoforms expanding functional versatility in organisms including Zebrafish, Xenopus laevis, and primates.

Clinical Significance and Mutations

Mutations, polymorphisms, or dysregulation of specific ATG genes are implicated in human diseases studied at centers such as Mayo Clinic, Johns Hopkins Hospital, and university hospitals. Loss-of-function variants in certain ATG family members correlate with neurodegenerative disorders characterized in cohorts examined by groups at Massachusetts General Hospital and research consortia focused on Alzheimer's disease, Parkinson's disease, and Huntington's disease. Altered ATG expression affects host responses to pathogens researched by teams at Centers for Disease Control and Prevention and Pasteur Institute, linking autophagy to immunity against intracellular bacteria like Listeria monocytogenes and viruses including Influenza A virus and Herpes simplex virus. In oncology, ATG-mediated autophagy can have tumor-promoting or tumor-suppressive roles depending on context, with clinical trials at institutions such as Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center testing autophagy modulators in combination with chemotherapies and targeted agents like inhibitors of BRAF and EGFR.

Biotechnological Applications

Researchers exploit ATG pathways for therapeutic and synthetic biology applications. Drug discovery programs at pharmaceutical companies like Roche, Pfizer, and Novartis screen for small molecules that inhibit or induce autophagy via ATG targets, aiming to enhance chemotherapy response or clear aggregated proteins. Gene therapy approaches using vectors from Adeno-associated virus platforms and genome editing with CRISPR-Cas9 enable modulation of ATG genes in preclinical models such as NOD mice and patient-derived xenografts studied at translational centers. Industrial biotechnology projects employ autophagy manipulation in cell lines like HEK293 and CHO cells to improve recombinant protein production, bioprocess stability, and stress tolerance.

Detection and Diagnostic Methods

Detection of ATG proteins and monitoring autophagic activity utilize biochemical, imaging, and genetic assays standardized in laboratories affiliated with Cold Spring Harbor Laboratory, European Molecular Biology Laboratory, and clinical pathology units in university medical centers. Common methods include immunoblotting for lipidated LC3 isoforms and p62/SQSTM1 turnover, fluorescence microscopy with GFP-LC3 reporters in cell lines and transgenic Mus musculus models, electron microscopy to visualize double-membrane autophagosomes, and proteomic analyses using mass spectrometry platforms at facilities like EMBL-EBI and Broad Institute. Genetic testing for pathogenic variants employs next-generation sequencing panels and databases curated by organizations such as ClinVar and international consortia focused on rare disease genetics.

History and Research Developments

Key milestones include the genetic dissection of autophagy in yeast by researchers at institutions including Osaka University and Tokyo University, the cloning of Beclin 1 by teams at The Rockefeller University, and the recognition of autophagy’s relevance to human disease culminating in awards and symposia organized by bodies like the Nobel Assembly and specialized societies. Recent advances integrate high-resolution cryo-electron microscopy from groups at MRC Laboratory of Molecular Biology with systems biology approaches at Stanford University and MIT to map ATG protein interactions and dynamics. Ongoing research emphasizes cross-talk with vesicular trafficking proteins such as SNAREs, lipid metabolism regulators, and ubiquitin ligases studied at collaborative networks spanning academic, clinical, and industry labs.

Category:Genes